CA Patent

CA3078652A1 — Semaglutide in medical therapy

Assigned to Novo Nordisk AS · Expires 2019-04-18 · 7y expired

What this patent protects

The present invention relates to semaglutide for use in weight management.

USPTO Abstract

The present invention relates to semaglutide for use in weight management.

Drugs covered by this patent

Ozempic (semaglutide) · Novo Nordisk

Patent Metadata

Patent number: CA3078652A1
Jurisdiction: CA
Classification: —
Expires: 2019-04-18
Drug substance claim: No
Drug product claim: No
Assignee: Novo Nordisk AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.